145 related articles for article (PubMed ID: 17698656)
1. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice.
Gómez CE; Nájera JL; Domingo-Gil E; Ochoa-Callejero L; González-Aseguinolaza G; Esteban M
J Gen Virol; 2007 Sep; 88(Pt 9):2473-2478. PubMed ID: 17698656
[TBL] [Abstract][Full Text] [Related]
2. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
3. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.
Nájera JL; Gómez CE; Domingo-Gil E; Gherardi MM; Esteban M
J Virol; 2006 Jun; 80(12):6033-47. PubMed ID: 16731942
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
Kanesa-thasan N; Smucny JJ; Hoke CH; Marks DH; Konishi E; Kurane I; Tang DB; Vaughn DW; Mason PW; Shope RE
Vaccine; 2000 Oct; 19(4-5):483-91. PubMed ID: 11027812
[TBL] [Abstract][Full Text] [Related]
5. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.
Guerra S; Nájera JL; González JM; López-Fernández LA; Climent N; Gatell JM; Gallart T; Esteban M
J Virol; 2007 Aug; 81(16):8707-21. PubMed ID: 17537851
[TBL] [Abstract][Full Text] [Related]
6. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
7. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.
Gómez CE; Nájera JL; Krupa M; Esteban M
Curr Gene Ther; 2008 Apr; 8(2):97-120. PubMed ID: 18393831
[TBL] [Abstract][Full Text] [Related]
8. Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases.
Perdiguero B; Pérez P; Marcos-Villar L; Albericio G; Astorgano D; Álvarez E; Sin L; Gómez CE; García-Arriaza J; Esteban M
J Mol Biol; 2023 Aug; 435(15):168173. PubMed ID: 37301278
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy of replication-defective adenovirus and Nyvac poxvirus as vaccine vectors in mice.
Gonin P; Oualikene W; Fournier A; Eloit M
Vaccine; 1996 Aug; 14(11):1083-7. PubMed ID: 8879106
[TBL] [Abstract][Full Text] [Related]
10. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
11. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
[TBL] [Abstract][Full Text] [Related]
12. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.
Price PJ; Torres-Domínguez LE; Brandmüller C; Sutter G; Lehmann MH
Vaccine; 2013 Sep; 31(39):4231-4. PubMed ID: 23523404
[TBL] [Abstract][Full Text] [Related]
13. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines.
Welter J; Taylor J; Tartaglia J; Paoletti E; Stephensen CB
J Virol; 2000 Jul; 74(14):6358-67. PubMed ID: 10864646
[TBL] [Abstract][Full Text] [Related]
14. Enhancing poxvirus vectors vaccine immunogenicity.
García-Arriaza J; Esteban M
Hum Vaccin Immunother; 2014; 10(8):2235-44. PubMed ID: 25424927
[TBL] [Abstract][Full Text] [Related]
15. Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice.
Konishi E; Kurane I; Mason PW; Shope RE; Ennis FA
Virology; 1997 Jan; 227(2):353-60. PubMed ID: 9018134
[TBL] [Abstract][Full Text] [Related]
16. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
17. Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses.
Karkhanis LU; Ross TM
Curr Pharm Des; 2007; 13(19):2015-23. PubMed ID: 17627535
[TBL] [Abstract][Full Text] [Related]
18. A mouse model based on replication-competent Tiantan vaccinia expressing luciferase/HIV-1 Gag fusion protein for the evaluation of protective efficacy of HIV vaccine.
Huang Y; Qiu C; Liu LX; Feng YM; Zhu T; Xu JQ
Chin Med J (Engl); 2009 Jul; 122(14):1655-9. PubMed ID: 19719967
[TBL] [Abstract][Full Text] [Related]
19. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.
Esteban M
Hum Vaccin; 2009 Dec; 5(12):867-71. PubMed ID: 19786840
[TBL] [Abstract][Full Text] [Related]
20. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
